Transcriptomics Market

Transcriptomics Market Size:

The global transcriptomics market size reached USD 7.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach USD 11.8 Billion by 2032, exhibiting a growth rate (CAGR) of 5.44% during 2024-2032. The market is witnessing steady growth, mainly boosted by innovations in bioinformatics and sequencing technologies. Moreover, amplifying research in personalized medicine and genomics further fuels demand. At present, North America holds the largest market share, attributed to the presence of prominent companies and increased investments in biotechnology sector.

Transcriptomics is the analysis of the ribonucleic acid (RNA) transcripts produced by the genotype of any organism at a specific time, condition, or cell. It links the genome, the proteome, and the cellular phenotype. Transcriptomics encompasses everything relating to RNAs, including their transcription and expression levels, functions, locations, trafficking, and degradation. Transcriptomics utilizes microarray analysis, real-time quantitative polymerase chain reaction (Q-PCR), and sequencing technologies to determine the transcriptional structure of genes. It also assists researchers in characterizing transcriptional activity, focuses on a subset of relevant target genes and transcripts, and identifies genes and pathways that respond to and counteract biotic and abiotic environmental stresses.

Transcriptomics Market Trends:

Integration of Transcriptomics with ML and AI

According to the transcriptomics market forecast, the incorporation of machine learning (ML) and artificial intelligence (AI) is anticipated to revolutionize data analysis in this field. AI-powered tools can effectively interpret large datasets, diagnosing complicated correlations as well as patterns in gene expression. According to research article published in the journal Nature Methods in February 2024, researchers at the University of Toronto have developed single cell generative pretrained transformer (scGPT), an innovative AI model that can efficiently predict the impacts of manipulating specific genes and can integrate different batches of data together to detect otherwise untraceable cell types. Moreover, this approach bolsters disease comprehension, drug discovery, and biomarker identification. In addition, machine learning models can project disease outcomes on the basis of transcriptomic data, significantly improving personalized medicine. As the intricacy of transcriptomic data elevates, ML and AI are rapidly becoming requisite for acquiring meaningful insights, positioning this integration as a key trend driving the transcriptomics market growth significantly. Furthermore, the accelerating adoption of AI and ML in transcriptomics is anticipated to boost advancements in precision medicine and targeted therapies, enabling more precise and faster identification of disease mechanisms and novel therapeutic targets.

Advancements in Single-Cell Transcriptomics

The development of single-cell transcriptomics has revolutionized the global transcriptomics market by facilitating the comprehensive study of gene expression at the individual cell level. This trend is rapidly gaining momentum as researchers are actively seeking ways to interpret cellular heterogeneity in various diseases such as neurological disorders and cancer. The growing prevalence of cancer further fuels this trend, as single-cell transcriptomics is requisite for understanding tumor complexity and developing personalized treatments, resultantly contributing to the expansion of transcriptomics market share As per industry reports, more than 1.9 million new cancer cases were projected to be diagnosed in the U.S. in the year 2023, with 609,820 estimated deaths. Furthermore, single-cell analysis provides accurate interpretation of cell behavior, resulting in the discovery of innovative biomarkers and new therapeutic targets. In addition, with increasing enhancements in technology and significant reduction in costs, the need for single-cell transcriptomics is substantially accelerating, bolstering the market expansion in both clinical applications and academic research activities.

Increasing Application in Personalized Medicine

The growing integration of transcriptomics in clinical research is transforming treatment protocols across healthcare sectors. The transcriptomics market analysis indicates that this field of study is rapidly being applied in personalized medicine, where comprehending individual gene expression profiles contribute to tailoring treatment methodologies. This trend is primarily propelled by the escalating interest in precision healthcare, especially in rare disorders and cancer. As per industry reports, functional precision medicine can effectively identify effective treatments for almost 55% of adult patients with blood cancers, including lymphoma and leukemia, who have not responded to conventional treatment methods. Moreover, by locating patient-specific biomarkers, transcriptomics facilitates the development of targeted therapies and minimizes the risk of adverse drug reactions. As a result, several healthcare providers as well as pharmaceutical firms are increasingly adopting transcriptomic techniques to formulate individualized treatment strategies. Furthermore, as personalized medicine becomes more prevailing, this field is anticipated to play a crucial role, spurring the demand globally and contributing to a positive transcriptomics market outlook. 

Transcriptomics Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, technology, application and end user.

Breakup by Type:

• Instruments
• Consumables
• Software
• Services
   

Breakup by Technology:

• Microarray
• Real-Time Quantitative Polymerase Chain Reaction (Q-PCR)
• Sequencing Technologies
   

Breakup by Application:

• Diagnostics and Disease Profiling
• Drug Discovery
• Others
   

Breakup by End User:

• Academic and Research Institutes
• Pharmaceutical Companies
• Biotechnology Companies
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the transcriptomics industry include:

• Agilent Technologies Inc.
• Becton Dickinson and Company
• BGI Group
• Bio-Rad Laboratories Inc.
• Biospyder Technologies Inc.
• Illumina Inc.
• Nanostring Technologies Inc.
• Qiagen
• Roche Holding AG
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.
   

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Transcriptomics Market News:

• In May 2024, Bruker Corporation, a major scientific instruments company for material and molecular science, announced strategic acquisition of NanoString Technologies, Inc., a leading gene expression analysis and spatial transcriptomics provider, with an investment of $392.6 million. As per the agreement, Bruker acquired AtoMx, nCounter, GeoMx, and CosMx product lines.
• In April 2024, Lexogen, a prominent biotechnology company, launched its new FFPE Transcriptomics line, encompassing QuantSeq FFPE 3' mRNA-Seq Library Prep Kit for gene expression profiling, CORALL FFPE Whole Transcriptome RNA-Seq , and SPLIT One-Step FFPE RNA Extraction Kit.

Transcriptomics Market Report Scope:

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the transcriptomics market from 2018-2032.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the global transcriptomics market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the transcriptomics industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.